Champions Oncolog (CSBR) Stock Price, Quote & News

Company Profile

Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotec...

Industry: Biotechnology

Sector: Healthcare

Phone: 201 808 8400

Website: www.championsoncology.com

Address:

One University Plaza, Suite 307, Hackensack, United States

focafoca99 Apr. 9 at 9:09 PM

$CSBR will present eight AACR posters focused on response and resistance modeling across several oncology settings.

0 · Reply

Ned__ryerson Apr. 9 at 6:14 PM

$CSBR https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/champions-oncology-to-present-new-data-on-predicting-response-and-res-1156457 These guys seem to be moving forward while their stock languishes.

0 · Reply

zerodayrounder Apr. 2 at 4:02 PM

$CSBR how is Lumin different than LTRN withzeta.ai ?

0 · Reply

zerodayrounder Mar. 31 at 3:56 PM

$CSBR this thing is going to have a huge run at some point ... the SaaS biz and the AI biotech drug discovery .... none of that is priced ... but this is probably the sleepiest name out there.

1 · Reply

OfficialStocktwitsUser Mar. 28 at 4:46 AM

$CSBR RSI: 44.75, MACD: -0.1068 Vol: 0.16, MA20: 5.94, MA50: 6.31 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

PenkeInvesting Mar. 19 at 10:52 PM

Fundamental analysis of $CSBR (CHAMPIONS ONCOLOGY, INC.) based on financial data and reported results. #CSBR

1 · Reply

Bulltrader988 Mar. 12 at 11:03 PM

$CSBR 👃👀 https://x.com/i/status/2032207068644721051

0 · Reply

Bulltrader988 Mar. 12 at 11:03 PM

$CSBR 👃👀 https://finsee.ai/earnings/csbr/2026/q3/en

0 · Reply

StocktwitsEarnings Mar. 12 at 8:24 PM

$CSBR Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.02 down -106.06% YoY • Reported revenue of $16.56M down -2.82% YoY • Champions Oncology remains on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the full fiscal year, while investing in data platform and discovery therapeutics initiatives, expecting margins to improve.

0 · Reply

Bulltrader988 Mar. 12 at 8:04 PM

$CSBR Lets hear the cc 👃👀

1 · Reply

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Mar 30, 2026, 10:55 AM EDT - 12 days ago

Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy

Mar 12, 2026, 4:01 PM EDT - 4 weeks ago

Champions Oncology Reports Revenue of $16.6 Million

Mar 5, 2026, 4:00 PM EST - 5 weeks ago

Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026

Dec 15, 2025, 4:00 PM EST - 4 months ago

Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million

Dec 8, 2025, 4:00 PM EST - 4 months ago

Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025

Sep 15, 2025, 4:50 PM EDT - 7 months ago

CORRECTION: Champions Oncology Reports Quarterly Revenue of $14.0 Million

Sep 15, 2025, 3:55 PM EDT - 7 months ago

Champions Oncology Reports Record Quarterly Revenue of $14.0 Million

Sep 10, 2025, 4:30 PM EDT - 7 months ago

Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025

Jul 23, 2025, 4:00 PM EDT - 9 months ago

Champions Oncology Reports Record Annual Revenue of $57 Million

Jul 21, 2025, 8:30 AM EDT - 9 months ago

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025

Jul 18, 2025, 8:30 AM EDT - 9 months ago

Champions Oncology Announces Appointment of New CEO

Jul 8, 2025, 8:30 AM EDT - 9 months ago

Champions Oncology Launches Radiopharmaceutical Services Platform, Expands Isotope License, and Screens More Than 30 PDX Models

Apr 28, 2025, 9:45 AM EDT - 1 year ago

Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Champions Oncology's Data Platform Gains Momentum through a Strategic Collaboration with Turbine

Mar 11, 2025, 3:55 PM EDT - 1 year ago

Champions Oncology Reports Record Quarterly Revenue of $17.0 Million Record Net Income of $4.5 Million

Mar 6, 2025, 4:00 PM EST - 1 year ago

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 11, 2025

Feb 18, 2025, 9:00 AM EST - 1 year ago

Champions Oncology Announces 17 Abstracts Accepted for Presentation at the 2025 American Association for Cancer Research Annual Meeting

Jan 8, 2025, 8:00 AM EST - 1 year ago

Champions Oncology Enhances Clinical Bioanalytical Services Portfolio with New Technology and Additional Leadership

Dec 11, 2024, 4:00 PM EST - 1 year ago

Champions Oncology Reports Quarterly Revenue of $13.5 Million Adjusted EBITDA of $1.1 Million

Dec 5, 2024, 4:30 PM EST - 1 year ago

Champions Oncology to Announce Second Quarter Financial Results on Wednesday, December 11, 2024

Oct 16, 2024, 10:55 AM EDT - 1 year ago

Champions Oncology Announces Agreement with Weill Cornell Medicine

Sep 11, 2024, 4:00 PM EDT - 1 year ago

Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

Sep 9, 2024, 4:00 PM EDT - 1 year ago

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024

Jul 18, 2024, 4:00 PM EDT - 1 year ago

Champions Oncology Reports Quarterly Revenue of $14.0 Million

Jul 11, 2024, 4:05 PM EDT - 1 year ago

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Thursday, July 18, 2024

Jun 4, 2024, 9:00 AM EDT - 2 years ago

Champions Oncology and Medicines Discovery Catapult Forge Partnership to Accelerate Radiopharmaceutical Therapeutics Development

Mar 12, 2024, 4:30 PM EDT - 2 years ago

Champions Oncology Reports Quarterly Revenue of $12.0 Million

Mar 7, 2024, 9:00 AM EST - 2 years ago

Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation

Mar 6, 2024, 4:35 PM EST - 2 years ago

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 12, 2024

Dec 12, 2023, 4:00 PM EST - 2 years ago

Champions Oncology Reports Quarterly Revenue of $11.6 Million

Dec 4, 2023, 4:30 PM EST - 2 years ago

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 12, 2023

Nov 2, 2023, 8:30 AM EDT - 2 years ago

Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification

Oct 17, 2023, 8:30 AM EDT - 2 years ago

Champions Oncology Announces the Addition of Brady Davis as President

Sep 13, 2023, 4:00 PM EDT - 2 years ago

Champions Oncology Reports Quarterly Revenue of $12.6 Million

Sep 11, 2023, 4:00 PM EDT - 2 years ago

Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 13, 2023

Aug 22, 2023, 8:30 AM EDT - 2 years ago

Champions Oncology Aannounces Remarkable Lineup of Speakers at Its Translational Oncology Symposium in Boston in September 2023

Aug 1, 2023, 8:45 AM EDT - 2 years ago

Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies

Jul 24, 2023, 4:00 PM EDT - 2 years ago

Champions Oncology Reports Quarterly Revenue of $13.1 Million

Jul 20, 2023, 4:00 PM EDT - 2 years ago

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 24, 2023

Apr 17, 2023, 8:30 AM EDT - 3 years ago

Champions Oncology Announces the Formation of Corellia AI, a Wholly Owned Biotech that Leverages Unique AI-Enabled Workflows for Novel Therapeutic Development

Apr 5, 2023, 9:50 AM EDT - 3 years ago

Champions Oncology Announces $5M Stock Repurchase Program

Mar 15, 2023, 3:50 PM EDT - 3 years ago

Champions Oncology Reports Quarterly Revenue of $12.8 Million

Mar 13, 2023, 8:30 AM EDT - 3 years ago

Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023

Dec 13, 2022, 4:00 PM EST - 3 years ago

Champions Oncology Reports Record Quarterly Revenue of $14.3 Million

Dec 9, 2022, 4:30 PM EST - 3 years ago

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022

Sep 8, 2022, 4:00 PM EDT - 3 years ago

Champions Oncology Reports Record Quarterly Revenue of $13.7 Million

Sep 6, 2022, 4:00 PM EDT - 3 years ago

Champions Oncology to Announce First Quarter Financial Results on Thursday, September 8, 2022

Jul 21, 2022, 4:00 PM EDT - 4 years ago

Champions Oncology Reports Quarterly Revenue of $12.9 Million

Jul 14, 2022, 4:00 PM EDT - 4 years ago

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

focafoca99 Apr. 9 at 9:09 PM

$CSBR will present eight AACR posters focused on response and resistance modeling across several oncology settings.

0 · Reply

Ned__ryerson Apr. 9 at 6:14 PM

0 · Reply

zerodayrounder Apr. 2 at 4:02 PM

$CSBR how is Lumin different than LTRN withzeta.ai ?

0 · Reply

zerodayrounder Mar. 31 at 3:56 PM

$CSBR this thing is going to have a huge run at some point ... the SaaS biz and the AI biotech drug discovery .... none of that is priced ... but this is probably the sleepiest name out there.

1 · Reply

OfficialStocktwitsUser Mar. 28 at 4:46 AM

0 · Reply

PenkeInvesting Mar. 19 at 10:52 PM

Fundamental analysis of $CSBR (CHAMPIONS ONCOLOGY, INC.) based on financial data and reported results. #CSBR

1 · Reply

Bulltrader988 Mar. 12 at 11:03 PM

$CSBR 👃👀 https://x.com/i/status/2032207068644721051

0 · Reply

Bulltrader988 Mar. 12 at 11:03 PM

$CSBR 👃👀 https://finsee.ai/earnings/csbr/2026/q3/en

0 · Reply

StocktwitsEarnings Mar. 12 at 8:24 PM

0 · Reply

Bulltrader988 Mar. 12 at 8:04 PM

$CSBR Lets hear the cc 👃👀

1 · Reply

Bulltrader988 Mar. 12 at 8:02 PM

$CSBR 👃👀 https://www.stocktitan.net/news/CSBR/champions-oncology-reports-revenue-of-16-6-lxof9tbfl0yy.html

0 · Reply

Bulltrader988 Mar. 12 at 7:58 PM

$CSBR I was long away... But today Im back... Took a small position for earnings today 👃👀 "...will report its financial and operational results for the third quarter ended January 31, 2026, on Thursday, March 12, 2026, after market close. ..." 👃👀 https://www.finanznachrichten.de/nachrichten-2026-03/67869783-champions-oncology-inc-champions-oncology-to-announce-third-quarter-financial-results-on-thursday-march-12-2026-200.htm

0 · Reply

zerodayrounder Mar. 12 at 1:29 PM

$CSBR -- tough compare against year ago quarter which had $5 million in license revenue ... but seems like H2 FY2026 revenue should be $35 million vs $29 million H1, for $64 milion vs $57 million FY2025. Maybe 16m revnue this quarter and 18m 4Q Updates on Corellia AI funding and/or data platform/Lumin bookings Stock seems washed out but wtfdik note partner Turbine AI raised 25M euros a few weeks ago and is working with large biopharmas https://www.prnewswire.com/news-releases/turbine-secures-25m-series-b-led-by-interactive-venture-partners-with-participation-from-beiersdorf-venture-capital-announces-first-immunology-partnership-with-top-10-pharma-company-302695118.html

0 · Reply

OfficialStocktwitsUser Feb. 21 at 12:58 PM

$CSBR RSI: 18.57, MACD: -0.2919 Vol: 0.63, MA20: 6.58, MA50: 6.76 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BillionerOfKing Feb. 20 at 4:05 PM

$CSBR Current Stock Price: $6.05 Contracts to trade: $5.0 CSBR Feb 20 2026 Call Entry: $0.90 Exit: $1.76 ROI: 96% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

zerodayrounder Feb. 18 at 5:35 PM

what is with this junk $CSBR ? are they ever gonna license out their data and/or raise capital for the biotech? Narrative is CRO orgs are gonna get smoked by AI.

1 · Reply

RaisaAlonso1048 Feb. 18 at 12:37 PM

$CSBR Specialty healthcare services with recurring revenue; growth limited but cash flows stable.

0 · Reply

OfficialStocktwitsUser Jan. 29 at 1:54 PM

$CSBR RSI: 69.16, MACD: 0.1474 Vol: 0.31, MA20: 6.95, MA50: 6.76 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Ned__ryerson Jan. 28 at 4:03 AM

$CSBR up big. Volume was light. It wants to pop. Just looking for a reason.

0 · Reply

OfficialStocktwitsUser Jan. 2 at 7:39 PM

$CSBR RSI: 54.55, MACD: 0.0801 Vol: 0.47, MA20: 6.73, MA50: 6.71 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Hemispheric Dec. 26 at 12:25 PM

$CSBR Price action signals that reliability now matters more than headline momentum. Efficiency initiatives must translate into measurable productivity. Demonstrated durability would lengthen investor time horizons. Without validation, volatility will remain persistent.

0 · Reply

SuperGreenToday Dec. 24 at 11:20 PM

$CSBR Share Price: $7.05 Contract Selected: May 15, 2026 $7.5 Calls Buy Zone: $0.77 – $0.95 Target Zone: $1.32 – $1.61 Potential Upside: 63% ROI Time to Expiration: 141 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	79.85M
Revenue (ttm)	56.94M
Net Income (ttm)	4.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	8.25%
Debt to Equity Ratio	0.00

Volume	30,200
Avg Vol	8,188
Day's Range	N/A - N/A
Shares Out	13.89M
Stochastic %K	16%
Beta	0.40
Analysts	Strong Buy
Price Target	$12.00